Intracel Corp. earlier this month presented a meta-analysis of three Phase III trials of its OncoVax autologous tumor cell vaccine to treat colon cancer that suggested the product improved recurrence-free survival and recurrence-free interval. Even though only one of the trials showed a benefit an individual basis, Intracel believes its meta-analysis is appropriate because all of the trials used the same control.

OncoVax is comprised of autologous tumor cells combined with bacille Calmette-Guerin (BCG). At the World Congress on Vaccines and Immunization in Liege, Belgium, Intracel presented an intent-to-treat meta-analysis of 723 patients showing that four OncoVax vaccinations significantly improved recurrence-free survival and the recurrence-free interval in patients with Stage II colon cancer who met compliance and protocol